Article in JNCI cancer spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
36 authors.
Cody Z WatlingDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, United States.
Jessica L PetrickSlone Epidemiology Center, Boston University, Boston, MA, United States.ORCID 0000-0001-6580-450X
Barry I GraubardDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, United States.ORCID 0000-0002-6787-1105
Xuehong ZhangSchool of Nursing, Yale University, New Haven, CT, United States.ORCID 0000-0002-8260-8508
Matthew J BarnettCancer Prevention Program, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, United States.ORCID 0000-0002-1028-1091
Julie E BuringDivision of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.ORCID 0000-0003-2648-8692
Yu ChenDepartment of Population Health, NYU Grossman School of Medicine, New York, NY, United States.ORCID 0000-0002-1519-4894
A Heather EliassenDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States.ORCID 0000-0002-3961-6609
J Michael GazianoDivision of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.ORCID 0000-0002-5384-9767
Jonathan N HofmannDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, United States.ORCID 0000-0002-1043-5812
Wen-Yi HuangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, United States.ORCID 0000-0002-4440-3368
Jae H KangChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.ORCID 0000-0003-4812-0557
Jill KoshiolDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, United States.ORCID 0000-0002-3832-6204
Erikka LoftfieldDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, United States.ORCID 0000-0002-3573-8748
I-Min LeeDivision of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.ORCID 0000-0002-1083-6907
Steven C MooreDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, United States.ORCID 0000-0002-8169-1661
Lorelei A MucciDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States.ORCID 0000-0002-2551-4927
Marian L NeuhouserCancer Prevention Program, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, United States.ORCID 0000-0002-3876-0000
Christina C NewtonDepartment of Population Science, American Cancer Society, Atlanta, GA, United States.ORCID 0000-0003-1471-5608
Julie R PalmerSlone Epidemiology Center, Boston University, Boston, MA, United States.ORCID 0000-0002-6534-335X
Mark P PurdueDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, United States.ORCID 0000-0003-1177-3108
Lynn RosenbergSlone Epidemiology Center, Boston University, Boston, MA, United States.ORCID 0000-0003-2760-2987
Howard D SessoDivision of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.ORCID 0000-0002-9698-9954
Martha ShrubsoleVanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, United States.ORCID 0000-0002-5591-7575
Lesley TinkerCancer Prevention Program, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, United States.
Matthew TripletteCancer Prevention Program, Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, United States.ORCID 0000-0001-7421-4720
Caroline Y UmDepartment of Population Science, American Cancer Society, Atlanta, GA, United States.ORCID 0000-0001-5449-6230
Kala VisvanathanJohns Hopkins School of Medicine, Baltimore, MD, United States.ORCID 0000-0002-0582-8005
Eleanor L WattsDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, United States.ORCID 0000-0001-9229-2589
Jean Wactawski-WendeDepartment of Epidemiology and Environmental Health, University at Buffalo, Buffalo, NY, United States.ORCID 0000-0003-3096-9595
Walter WillettDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States.ORCID 0000-0003-1458-7597
Fen WuDepartment of Population Health, NYU Grossman School of Medicine, New York, NY, United States.ORCID 0000-0003-0997-0890
Wei ZhengVanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, United States.ORCID 0000-0003-1226-070X
Peter T CampbellDepartment of Epidemiology & Population Health, Albert Einstein College of Medicine, New York, NY, United States.ORCID 0000-0002-5549-2036
Dinesh BarupalDepartment of Environmental Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, United States.ORCID 0000-0002-9954-8628
Katherine A McGlynnDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, United States.ORCID 0000-0003-2329-9933
Funding
WOMEN'S HEALTH INITIATIVE - CLINICAL COORDINATING CENTER: TASK AREA B - LONG LIFE STUDY VISIT 2 LIMITED HOME VISIT75N92021D00001 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ANDERSON, GARNET L. · 2021 to 2025
$52.0M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MARY Kay WASHINGTON · 2002 to 2026
$29.9M
Women's Health Study: Continued Follow-upR01CA047988 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E., LEE, I-MIN · 1991 to 2014
$28.2M
A Follow-up Study for Causes of Cancer in Black WomenU01CA164974 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Kimberly A. Bertrand, Yvette C Cozier · 2017 to 2026
$24.0M
Long Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3M
Southern Community Cohort StudyU01CA202979 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BLOT, WILLIAM J., SHRUBSOLE, MARTHA J. · 2016 to 2025
$22.0M
Physicians' Health Study II: Prevention Trial of VitaminsR01CA097193 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI GAZIANO, J. MICHAEL · 2002 to 2011
$15.7M
THE CAROTENE AND RETINOL EFFICACY TRIAL (CARET)U01CA063673 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GOODMAN, GARY E · 1994 to 2006
$13.0M
WOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC): TASK AREA A AND A275N92021D00002 · NHLBI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI WACTAWSKI-WENDE, JEAN · 2021 to 2025
$6.9M
WOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC) - TO EXERCISE OPTION PERIOD ONE (1) AND REVISE CONTRACT ARTICLES.75N92021D00004 · NHLBI · STANFORD UNIVERSITY · PI STEFANICK, MARCIA · 2021 to 2025
$6.5M
WOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC) - TO EXERCISE OPTION PERIOD ONE (1) AND REVISE CONTRACT ARTICLES.75N92021D00003 · NHLBI · OHIO STATE UNIVERSITY · PI JACKSON, REBECCA · 2021 to 2025
$5.0M
Women's Health Study: Continued Follow-UpR01HL080467 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E. · 2005 to 2010
$4.5M
Canadian Institutes of Health Research Fellowship #187861CARET U01CA63673, UM1CA167462, and U01CA167462Intramural Research Program of the Division of Cancer Epidemiology and Genetics, and contracts from the Division of Cancer Prevention, NCI, NIH, DHHSNational Heart, Lung, and Blood Institute, National Institutes of Health, U.S. Department of Health and Human Services through contracts 75N92021D00001, 75N92021D00002, 75N92021D00003, 75N92021D00004, 75N92021D00005National Institutes of Health Intramural ProgramNCI NIH HHS R01 CA034944NCI NIH HHS R01 CA040360NCI NIH HHS R01 CA047988NCI NIH HHS R01 CA097193NCI NIH HHS U01 167552NCI NIH HHS U01 CA063673NCI NIH HHS U01 CA164974NCI NIH HHS U01 CA167462NCI NIH HHS U01 CA182913NCI NIH HHS U01 CA202979NCI NIH HHS UM1 CA167462NCI NIH HHS UM1 CA182913NCI NIH HHS UM1 CA186107NHLBI NIH HHS 75N92021D00001NHLBI NIH HHS 75N92021D00002NHLBI NIH HHS R01 HL026490NHLBI NIH HHS R01 HL034595NHLBI NIH HHS R01 HL043851NHLBI NIH HHS R01 HL080467NHLBI NIH HHS RC1 HL099355NIDDK NIH HHS P30 DK058404NIEHS NIH HHS U24 ES035386NIH HHS U01CA164974NIH HHS U24ES035386PHS HHS CA34944, CA40360, CA097193, HL26490 and HL34595WHI NIH HHS 75N92021D00003WHI NIH HHS 75N92021D00004WHI NIH HHS 75N92021D00005WHS CA047988, CA182913, HL043851, HL080467 and HL099355
6 · The paper itself
Abstract
backgroundBile acids are produced in the liver and are important for lipid digestion. Higher-circulating bile acid levels, however, have been linked to metabolic disorders, inflammation, and gut microbiota dysbiosis, which have been implicated in liver carcinogenesis. To date, few epidemiological studies have explored the association between circulating bile acids and liver cancer risk.
methodsWe conducted a nested case-control study among 12 prospective cohort studies located in the United States. Fifteen prediagnostic circulating bile acids were measured from blood samples among 872 individuals who developed liver cancer and 872 matched control participants. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using multivariable-adjusted conditional logistic regression analysis of circulating bile acid levels and liver cancer risk.
resultsPrimary conjugated bile acid concentrations were positively associated with higher risk of liver cancer (OR per doubling in concentrations [log2] and 95% CI of glycocholic acid: 1.32, 1.24 to 1.40; glycochenodeoxycholic acid: 1.33, 1.24 to 1.43; taurocholic acid: 1.28, 1.22 to 1.35; and taurchenodeoxycholic acid: 1.32, 1.24 to 1.39). Secondary conjugated bile acids were also positively associated with liver cancer risk (doubling of concentrations OR ranged from 1.11 to 1.22). Unconjugated bile acid concentrations were generally not associated with liver cancer risk, except lithocholic acid (OR per doubling: 1.27, 1.16 to 1.39). When analyses were separated into the 2 main subtypes of liver cancer, hepatocellular carcinoma (HCC; 438 cases/438 controls) and intrahepatic cholangiocarcinoma (ICC; 111 cases/111 controls), significant heterogeneity was observed for primary conjugated bile acid concentrations (all P < .001) that showed positive significant associations with HCC but not ICC.
conclusionsThese results suggest that bile acids may be important markers of HCC risk and contribute to hepatocarcinogenesis; however, further research using serial measurements is needed.
Indexed as
Bile Acids and SaltsCarcinoma, HepatocellularLiver NeoplasmsAdultAgedCase-Control StudiesCholangiocarcinomaFemaleHumansLogistic ModelsMaleMiddle AgedOdds RatioProspective StudiesRisk FactorsUnited StatesBile Acids and Salts
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Pre-diagnostic circulating bile acid concentrations and liver cancer risk: a nested case-control analysis of 12 cohorts. · full record | Socratic